Progression of Hodgkin lymphoma and plasma cell neoplasms Report from the 2021 SH/EAHP workshop

Reza Nejati, Catalina Amador, Magdalena Czader, Elizabeth Thacker, Devang Thakkar, Sandeep S. Dave, Ahmet Dogan, Amy Duffield, John R. Goodlad, German Ott, Mariusz A. Wasik, Wenbin Xiao, James R. Cook

Research output: Contribution to journalReview articlepeer-review

Abstract

Objectives: To summarize cases submitted to the 2021 Society for Hematopathology/ European Association for Haematopathology Workshop under the categories of progression of Hodgkin lymphoma, plasmablastic myeloma, and plasma cell myeloma. Methods: The workshop panel reviewed 20 cases covered in this session. In addition, whole-exome sequencing (WES) and whole-genome RNA expression analysis were performed on 10 submitted cases, including 6 Hodgkin lymphoma and 4 plasma neoplasm cases. Results: The cases of Hodgkin lymphoma included transformed cases to or from various types of B-cell lymphoma with 1 exception, which had T-cell differentiation. The cases of plasma cell neoplasms included cases with plasmablastic progression, progression to plasma cell leukemia, and secondary B-lymphoblastic leukemia. Gene variants identified by WES included some known to be recurrent in Hodgkin lymphoma and plasma cell neoplasm. All submitted Hodgkin lymphoma samples showed 1 or more of these mutations: SOCS1, FGFR2, KMT2D, RIT1, SPEN, STAT6, TET2, TNFAIP3, and ZNF217. Conclusions: Better molecular characterization of both of these neoplasms and mechanisms of progression will help us to better understand mechanisms of progression and perhaps develop better prognostic models, as well as identifying novel therapeutic targets.

Original languageEnglish
Pages (from-to)598-613
Number of pages16
JournalAmerican Journal of Clinical Pathology
Volume159
Issue number6
DOIs
StatePublished - Jun 1 2023

Keywords

  • Hodgkin lymphoma
  • Plasma cell leukemia
  • Plasma cell neoplasm
  • Progression
  • Transformation

Fingerprint

Dive into the research topics of 'Progression of Hodgkin lymphoma and plasma cell neoplasms Report from the 2021 SH/EAHP workshop'. Together they form a unique fingerprint.

Cite this